Allogeneic anti-CD7 CAR-T cells (BEAM-201)
Phase 1Recruiting 0 watching 0 views this week💤 Quiet
28
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
T-Cell Acute Lymphoblastic Leukemia/Lymphoma
Conditions
T-Cell Acute Lymphoblastic Leukemia/Lymphoma
Trial Timeline
Apr 29, 2025 → May 30, 2031
NCT ID
NCT06934382About Allogeneic anti-CD7 CAR-T cells (BEAM-201)
Allogeneic anti-CD7 CAR-T cells (BEAM-201) is a phase 1 stage product being developed by Beam Therapeutics for T-Cell Acute Lymphoblastic Leukemia/Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06934382. Target conditions include T-Cell Acute Lymphoblastic Leukemia/Lymphoma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
5
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06934382 | Phase 1 | Recruiting |
Competing Products
20 competing products in T-Cell Acute Lymphoblastic Leukemia/Lymphoma